The BLBC presented low expressions of progesterone receptor (PR), estrogen receptor (ER), as well as human epidermal growth factor 2 receptor (HER2), thus also be recognized as a subtype of triple-negative breast cancer (TNBC) which takes up about 10–20% of all BC [5, 6]. This evidence concerns the gene ESR1 and triple-negative breast carcinoma.